News

Paula Rodriguez-Otero, MD, PhD, provides an overview of the phase 3 KarMMa-3 trial of idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma.

Neal Shore, MD, FACS, discusses a study aimed to investigate the real-world survival outcomes of men with metastatic castration-sensitive prostate cancer treated with either apalutamide or enzalutamide in the United States.

In an interview with Targeted Oncology, Shervin Tabrizi, MD, discussed the development of a 2-part priming strategy aimed at enhancing the sensitivity of liquid biopsies for cancer detection and monitoring.

A phase 1, first-in-human study is evaluating a novel CAR T-cell therapy in patients with ovarian cancer at Moffitt Cancer Center.

The biologics license application for denileukin diftitox has been resubmitted to the FDA for the treatment of cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The FDA has granted the supplemental new drug application of repotrectinib priority review.

A phase 2 trial for the treatment of gastric, esophageal, and gastroesophageal junction cancer is evaluating agenT-797 with botensilimab, balstilimab, ramucirumab, and paclitaxel.

Raajit K. Rampal, MD, PhD, discusses some of the key takeaways from the 2023 American Society of Hematology Annual Meeting and what he believes holds promise for the space in 2024.

Liposomal irinotecan with 5-fluorouracil, leucovorin, and oxaliplatin (NALIRIFOX) is now an FDA-approved treatment option for patients with metastatic pancreatic ductal adenocarcinoma.

In an interview, Ira Zackon, MD, emphasized the need for community-based, inclusive care, and the importance of utilizing technology to address disparities in the modern era of chronic lymphocytic leukemia treatment.

The FDA has granted fast track designation to BXCL701 with an immune checkpoint inhibitor for metastatic small cell neuroendocrine prostate cancer resistant to chemotherapy and showing no evidence of microsatellite instability.

Eric Schroeder, MD, discusses how treatments for patients with ovarian cancer have evolved in recent years.

In an interview with Targeted Oncology, Clara Hwang, MD, discussed the notable differences in molecular alterations observed in the retrospective cohort study among Black men with metastatic castration-resistant prostate cancer compared with White men.

There are currently no FDA-approved agents for relapsed peripheral T-cell lymphoma, and soquelitinib has the potential to fill an unmet need.

The phase 1 study of HEMO-CAR-T in patients with acute myeloid leukemia can proceed following the lifted clinical hold.

212PB-DOTAMTATE is the first targeted alpha therapy to receive a breakthrough therapy designation in this intent-to-treat population.

The FDA has accepted Xspray Pharma's resubmitted application for Dasynoc, a potential new treatment for chronic myeloid leukemia and acute lymphoblastic leukemia.

John Nakayama, MD, discusses the significance of the NRG GY018 study in endometrial cancer.

Chirag Shah, MD, discussed findings from the PREDICT study which looked at DCISionRT testing for patients with ductal carcinoma in situ breast cancer.

The study demonstrates the potential ctDNA holds for prognosis and risk stratification in patients with early-stage endometrial cancer.

Whole-exome sequencing identified genetic mutations associated with poorly differentiated thyroid cancer, paving a new path for research in the field.

The FLAURA2 study found that osimertinib with platinum-pemetrexed was more effective than osimertinib monotherapy in preventing central nervous system progression or death in patients with EGFR-mutated advanced non–small cell lung cancer.

Hatem Soliman, MD, discusses what unmet needs still have to be addressed in the HER2-positive breast cancer space.

In an interview with Targeted Oncology, Bruce Feinberg, DO, discussed the importance of real-world data, highlighting recent findings on tafasitamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma in the United States.

Goserelin is now included in the NCCN Breast Cancer Panel guidelines at 2 dosing schedules for ovarian function suppression in Version 1.2024.

For Gallbladder Cancer Awareness Month, Horacio J. Asbun, MD, and Domenech Asbun, MD, shared their thoughts and strategies for treating patients with this disease from the surgical and clinical sides.

Regina Barragan-Carrillo, MD, discusses findings from a large population-based study which found there to be significantly higher rates of nephrectomy among patients with renal cell carcinoma who had received prior thymectomy vs the incidence of nephrectomy overall.